| Id |
Subject |
Object |
Predicate |
Lexical cue |
| 15720817-1#17#32#diseaseC1519678 |
127-142 |
diseaseC1519678 |
denotes |
tumor expansion |
| 15720817-1#127#138#gene5340 |
237-248 |
gene5340 |
denotes |
plasminogen |
| 15720817-1#140#143#gene5340 |
250-253 |
gene5340 |
denotes |
Plg |
| 15720817-2#56#89#gene5054 |
346-379 |
gene5054 |
denotes |
plasminogen activator inhibitor-1 |
| 15720817-2#91#96#gene5054 |
381-386 |
gene5054 |
denotes |
PAI-1 |
| 15720817-2#101#119#diseaseC1519670 |
391-409 |
diseaseC1519670 |
denotes |
tumor angiogenesis |
| 15720817-0#5#38#gene5054 |
500-1202 |
gene5054 |
denotes |
progression. By generating immunodeficient mice (in Rag-1-/- or nude background) deleted for PAI-1 gene (PAI-1-/-), we have evaluated the impact of host PAI-1 deficiency on the tumorigenicity of two malignant human skin keratinocyte cell lines HaCaT II-4 and HaCaT A5-RT3 forming low-grade and high-grade carcinomas, respectively. When using the surface transplantation model, angiogenesis and tumor invasion of these two cell lines are strongly reduced in PAI-1-deficient mice as compared to the wild-type control animals. After subcutaneous injection in PAI-1-/- mice, the tumor incidence is reduced for HaCaT II-4 cells, but not for those formed by HaCaT A5-RT3 cells. These data indicate that PAI-1 |
| 15720817-4#14#29#diseaseC0021051 |
527-542 |
diseaseC0021051 |
denotes |
immunodeficient |
| 15720817-4#39#44#gene5896 |
552-557 |
gene5896 |
denotes |
Rag-1 |
| 15720817-4#80#85#gene5054 |
593-598 |
gene5054 |
denotes |
PAI-1 |
| 15720817-4#92#97#gene5054 |
605-610 |
gene5054 |
denotes |
PAI-1 |
| 15720817-4#140#145#gene5054 |
653-658 |
gene5054 |
denotes |
PAI-1 |
| 15720817-0#54#68#diseaseC0699893 |
1281-1295 |
diseaseC0699893 |
denotes |
skin carcinoma |
| 127#138#gene534017#32#diseaseC1519678 |
15720817-1#127#138#gene5340 |
15720817-1#17#32#diseaseC1519678 |
associated_with |
plasminogen,tumor expansion |
| 140#143#gene534017#32#diseaseC1519678 |
15720817-1#140#143#gene5340 |
15720817-1#17#32#diseaseC1519678 |
associated_with |
Plg,tumor expansion |
| 140#145#gene505414#29#diseaseC0021051 |
15720817-4#140#145#gene5054 |
15720817-4#14#29#diseaseC0021051 |
associated_with |
PAI-1,immunodeficient |
| 39#44#gene589614#29#diseaseC0021051 |
15720817-4#39#44#gene5896 |
15720817-4#14#29#diseaseC0021051 |
associated_with |
Rag-1,immunodeficient |
| 5#38#gene505454#68#diseaseC0699893 |
15720817-0#5#38#gene5054 |
15720817-0#54#68#diseaseC0699893 |
associated_with |
"progression. By generating immunodeficient mice (in Rag-1-/- or nude background) deleted for PAI-1 gene (PAI-1-/-), we have evaluated the impact of host PAI-1 deficiency on the tumorigenicity of two malignant human skin keratinocyte cell lines HaCaT II-4 and HaCaT A5-RT3 forming low-grade and high-grade carcinomas, respectively. When using the surface transplantation model, angiogenesis and tumor invasion of these two cell lines are strongly reduced in PAI-1-deficient mice as compared to the wild-type control animals. After subcutaneous injection in PAI-1-/- mice, the tumor incidence is reduced for HaCaT II-4 cells, but not for those formed by HaCaT A5-RT3 cells. These data indicate that PAI-1",skin carcinoma |
| 56#89#gene5054101#119#diseaseC1519670 |
15720817-2#56#89#gene5054 |
15720817-2#101#119#diseaseC1519670 |
associated_with |
plasminogen activator inhibitor-1,tumor angiogenesis |
| 80#85#gene505414#29#diseaseC0021051 |
15720817-4#80#85#gene5054 |
15720817-4#14#29#diseaseC0021051 |
associated_with |
PAI-1,immunodeficient |
| 91#96#gene5054101#119#diseaseC1519670 |
15720817-2#91#96#gene5054 |
15720817-2#101#119#diseaseC1519670 |
associated_with |
PAI-1,tumor angiogenesis |
| 92#97#gene505414#29#diseaseC0021051 |
15720817-4#92#97#gene5054 |
15720817-4#14#29#diseaseC0021051 |
associated_with |
PAI-1,immunodeficient |
